Literature DB >> 17994381

Prenatal control of Hb Bart's disease in southern China.

Can Liao1, Qiuming Li, Jiaxue Wei, Qiong Feng, Jian Li, Yining Huang, Dongzhi Li.   

Abstract

Alpha-thalassemia (thal) is one of the most common genetic diseases and is widely distributed in southern China. Fetuses with homozygous alpha(0)-thal, known as Hb Bart's (gamma(4)) disease, usually die during the last trimester of gestation, and the affected pregnancies are frequently associated with serious maternal morbidity and mortality. Prenatal diagnosis is needed for early detection of this disease in couples at-risk. This can be performed by invasive fetal sampling or by serial ultrasonography to detect affected fetuses followed by invasive testing. Of 122 at-risk families who received prenatal testing, 98 (80.3%) chose ultrasonography, and 24 (19.7%) chose direct invasive testing. In all, 28 affected pregnancies were detected and terminated. Ultrasonography is now playing a major role in prenatal control of Hb Bart's disease in our region, and limits the invasive procedures to the few patients identified to be at high risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994381     DOI: 10.1080/03630260701634463

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  3 in total

1.  Implementation of newborn screening for hemoglobin h disease in mainland china.

Authors:  Xing-Mei Xie; Jian-Ying Zhou; Jian Li; Ru Li; Can Liao; Dong-Zhi Li
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-20       Impact factor: 0.900

Review 2.  Clinical manifestations of α-thalassemia.

Authors:  Elliott P Vichinsky
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

3.  Molecular analysis of a large novel deletion causing α+-thalassemia.

Authors:  Jianlong Zhuang; Jie Tian; Jitao Wei; Yu Zheng; Qianmei Zhuang; Yuanbai Wang; Qingyue Xie; Shuhong Zeng; Geng Wang; Yanchao Pan; Yuying Jiang
Journal:  BMC Med Genet       Date:  2019-05-06       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.